Biomarin

Activist investor Elliott targets drugmaker BioMarin -sources
Activist investor Elliott targets drugmaker BioMarin -sources
Reuters
Biomarin
Elliott Management
Flag link:
BioMarin’s longtime CEO Jean-Jacques Bienaimé hands the reins to Genentech’s Alexander Hardy
BioMarin’s longtime CEO Jean-Jacques Bienaimé hands the reins to Genentech’s Alexander Hardy
Fierce Pharma
Biomarin
Pharma CEOs
Jean-Jacques Bienaimé
Alexander Hardy
Genentech
Flag link:
BioMarin's share prices fluctuate following Phase 3 clinical trial results
BioMarin's share prices fluctuate following Phase 3 clinical trial results
Yahoo/Investing.com
Biomarin
Roctavian
clinical trials
Flag link:
With Roctavian as a launching pad, BioMarin looks to up pace of new drug filings
With Roctavian as a launching pad, BioMarin looks to up pace of new drug filings
Fierce Biotech
Biomarin
Roctavian
hemophilia A
Voxzogo
achrondoplasia
drug development
gene therapy
Flag link:
Voxzogo saves the day for Biomarin
Voxzogo saves the day for Biomarin
EP Vantage
Biomarin
hemophilia A
gene therapy
Roctavian
Voxzogo
Flag link:
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Flag link:
PTC, chasing BioMarin, posts phase 3 rare disease win but fails to silence skeptics
PTC, chasing BioMarin, posts phase 3 rare disease win but fails to silence skeptics
Fierce Biotech
PTC Therapeutics
Biomarin
PKU
clinical trials
Flag link:
Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch
Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch
Forbes
gene therapy
drug approvals
Biomarin
Bluebird Bio
FDA
Flag link:
BioMarin opens €38m expansion at Irish manufacturing site
BioMarin opens €38m expansion at Irish manufacturing site
Biopharma Reporter
Biomarin
Ireland
drug manufacturing
Flag link:
BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia
BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia
BioSpace
Biomarin
BridgeBio
achondroplasia
FDA
Voxzogo
Flag link:
FDA delays review of BioMarin's hemophilia gene therapy after data update
FDA delays review of BioMarin's hemophilia gene therapy after data update
Endpoints
Biomarin
gene therapy
hemophilia A
FDA
valrox
Flag link:
Go or no go? Vaccines and neurology up for discussion
Go or no go? Vaccines and neurology up for discussion
EP Vantage
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Flag link:
JPM Day 1: Highlights
JPM Day 1: Highlights
BioSpace
JPMHC 2023
Sarepta Therapeutics
Biomarin
Alnylam
JNJ
Arrowhead Pharmaceuticals
Novartis
Bristol Myers Squibb
Flag link:
5 FDA decisions to watch in the first quarter
5 FDA decisions to watch in the first quarter
BioPharma Dive
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests
BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests
Fierce Biotech
Biomarin
gene therapy
FDA
hemophilia
Roctavian
Flag link:
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Fierce Pharma
ICER
drug pricing
gene therapy
Biomarin
CSL
Bluebird Bio
hemophilia
Flag link:
BioMarin gets FDA decision date for hemophilia gene therapy, but questions on review remain
BioMarin gets FDA decision date for hemophilia gene therapy, but questions on review remain
BioPharma Dive
Biomarin
FDA
hemophilia A
gene therapy
Roctavian
Flag link:
BioMarin lays off 120 employees to save $50M a year, with US operations hardest hit
BioMarin lays off 120 employees to save $50M a year, with US operations hardest hit
Fierce Biotech
Biomarin
layoffs
Flag link:
BioMarin Banks on More Robust Data in Hemophilia A Resubmission
BioMarin Banks on More Robust Data in Hemophilia A Resubmission
BioSpace
Biomarin
FDA
hemophilia A
valoctocogene roxaparvovec
Flag link:

Pages